Definitive Healthcare Corp. (DH) · Nov 5, 2026 · Earnings
Beat — Adj. EPS $0.06 vs ~$0.04 consensus
Definitive Healthcare’s Q3 earnings beat profit expectations, but revenue fell 9%, margins weakened and the company offered no guidance.
Definitive Healthcare is a healthcare data and analytics company trying to stabilize a shrinking revenue base while integrating new leadership and operating under the shadow of Advent’s proposed take-private transaction. The company had already warned that 2026 revenue would decline amid disruption in the healthcare claims-data market, and Clay Ritchey became CEO in September as part of a leadership reset.
The quarter beat the published profit bar, but only narrowly on revenue. Revenue of $54.7 million was just above the published consensus of roughly $54.57 million, while adjusted EPS of $0.06 exceeded the roughly $0.04 expectation. The company had guided Q3 revenue to $54.0–$55.0 million and adjusted net income to $5.5–$6.5 million, so execution landed inside its own range rather than resetting the business outlook.
| Q3 2026 | Q3 2025 | Consensus | |
|---|---|---|---|
| Revenue (Financial Highlights) | $54.7M | $60.0M | $54.57M |
| Adjusted net income per share (Reconciliation) | $0.06 | $0.07 | $0.04 |
| Adjusted EBITDA (Financial Highlights) | $15.7M | $18.9M | |
| Adjusted EBITDA margin (Financial Highlights) | 29% | 32% | |
| Cash flow from operations (Financial Highlights) | $11.4M | $15.7M |
The core operating trend remains weak. Revenue fell 9% year over year, adjusted EBITDA declined about 17%, and the margin contracted three percentage points to 29%. That means the profit beat came from outperforming a low bar and tighter cost control, not from renewed top-line momentum.
Cash generation also deteriorated despite the cleaner GAAP loss. Operating cash flow fell to $11.4 million from $15.7 million, while adjusted net income declined to $8.8 million from $9.7 million. The smaller net loss is therefore not evidence of a broad operating recovery; the business is still producing cash, but at a lower rate.
The missing outlook is understandable but leaves the turnaround harder to judge. Definitive Healthcare withheld guidance and its conference call because Advent’s September 2 non-binding $1.02-per-share buyout indication is under review, a development already known before this earnings release. That makes the omission mostly confirmation rather than new information, but it removes the clearest near-term benchmark for whether the new CEO can reverse the revenue decline. 〔0〕
Bottom line: Definitive Healthcare beat a modest quarterly profit expectation, but the underlying business is still shrinking and becoming less profitable. The result modestly improves near-term execution credibility without changing the larger turnaround story.ank
Advent special committee decision on the buyout proposal
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!